10 drugmakers are working together to develop a treatment based on the blood of COVID-19 survivors, and they plan to start testing in humans next month

Potential coronavirus vaccines take a long time to develop. In the meantime, the hunt for COVID-19 treatments is fully underway. 10 biopharma companies — including Takeda, Japan’s largest drugmaker — are collaborating to advance one plasma-based therapy. The companies hope to start human testing in July, finish the trial by the fall, and gain approval by year’s end. If it works, the treatment may help combat a second wave of the virus. The coalition is now seeking volunteers who have recovered from COVID-19 to donate plasma.  For more stories like this, sign up here for our healthcare newsletter

Leave a Reply